Identification of amino acid residues involved in the binding of Huperzine A to cholinesterases.
Huperzine A, a potential agent for therapy in Alzheimer's disease and for prophylaxis of organophosphate toxicity, has recently been characterized as a reversible inhibitor of cholinesterases. To examine the specificity of this novel compound in more detail, we have examined the interaction of the 2 stereoisomers of Huperzine A with cholinesterases and site-specific mutants that detail the involvement of specific amino acid residues. Inhibition of fetal bovine serum acetylcholinesterase by (-)-Huperzine A was 35-fold more potent than (+)-Huperzine A, with KI values of 6.2 nM and 210 nM, respectively. In addition, (-)-Huperzine A was 88-fold more potent in inhibiting Torpedo acetylcholinesterase than (+)-Huperzine A, with KI values of 0.25 microM and 22 microM, respectively. Far larger KI values that did not differ between the 2 stereoisomers were observed with horse and human serum butyrylcholinesterases. Mammalian acetylcholinesterase, Torpedo acetylcholinesterase, and mammalian butyrylcholinesterase can be distinguished by the amino acid Tyr, Phe, or Ala in the 330 position, respectively. Studies with mouse acetylcholinesterase mutants, Tyr 337 (330) Phe and Tyr 337 (330) Ala yielded a difference in reactivity that closely mimicked the native enzymes. In contrast, mutation of the conserved Glu 199 residue to Gln in Torpedo acetylcholinesterase produced only a 3-fold increase in KI value for the binding of Huperzine A.(ABSTRACT TRUNCATED AT 250 WORDS)
Saxena
A
A
Division of Biochemistry, Walter Reed Army Institute of Research, Washington, D.C. 20307.
Qian
N
N
Kovach
I M
IM
Kozikowski
A P
AP
Pang
Y P
YP
Vellom
D C
DC
Radić
Z
Z
Quinn
D
D
Taylor
P
P
Doctor
B P
BP
D000110:Acetylcholinesterase / Q000737:chemistry / Q000378:metabolism; D000470:Alkaloids; D000596:Amino Acids / Q000032:analysis* / Q000378:metabolism; D000818:Animals; D001665:Binding Sites; D002091:Butyrylcholinesterase / Q000737:chemistry / Q000378:metabolism; D002800:Cholinesterase Inhibitors / Q000378:metabolism* / Q000494:pharmacology; D002802:Cholinesterases / Q000737:chemistry* / Q000378:metabolism*; D004563:Electrochemistry; D006801:Humans; D006860:Hydrogen Bonding; D007700:Kinetics; D051379:Mice; D008958:Models, Molecular; D011994:Recombinant Proteins / Q000737:chemistry / Q000378:metabolism; D012717:Sesquiterpenes / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D013237:Stereoisomerism; D013816:Thermodynamics; D014101:Torpedo
D000470:Alkaloids; D000596:Amino Acids; D002800:Cholinesterase Inhibitors; D011994:Recombinant Proteins; D012717:Sesquiterpenes; C050426:huperzine A; D000110:Acetylcholinesterase; D002091:Butyrylcholinesterase; D002802:Cholinesterases